Saturday 17 October 2026
Export AKTX’s income statement to Excel — free account
Akari Therapeutics PLC
AKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 60.3%, free cash flow grew 4.51% and total debt fell 1.00%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
8.18
0.66
−7.47%
Follow AKTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(197.24%) | (68.43%) | (155.28%) | (140.09%) | |
| (65.57%) | (35.14%) | (66.11%) | (69.16%) | ||
ROIC |
(58.05%) | (45.48%) | (159.65%) | (167.93%) | |
Return on Tangible Assets |
124.96% | 251.10% | 285.45% | 551.77% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(11.82) | (12.56) | (7.35) | (6.01) | |
Free Cash Flow |
(9.65) | (10.57) | (10.91) | (10.76) | |
| Other line items | |||||
Cash ROIC |
(37.27%) | (30.84%) | (63.38%) | (39.79%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.37) | (0.17) | (0.13) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(55.22) | (18.20) | (30.90) | (31.46) | |
Operating CF/Net income |
0.61 | 0.61 | 0.39 | 0.35 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(11.82) | (12.56) | (7.35) | (6.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates